20 stories mentioning DGXUpdated 59m ago
Every FINWIRES story that references DGX, newest first.
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $244.93, according to analysts polled by FactSet.Price: $232.91, Change: $-2.31, Percent Change: -0.98%
Healthcare stocks advanced late Thursday afternoon with the NYSE Healthcare Index gaining 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 1.1%.The iShares Biotechnology ETF (IBB) added 1%.In corporate news, Thermo Fisher Scientific (TMO) shares jumped 8.9% after fiscal Q2 adjusted earnings and revenue topped estimates.Quest Diagnostics (DGX) shares rose 8% after Q2 adjusted earnings and revenue exceeded market consensus.Neuphoria Therapeutics (NEUP) agreed to be acquired by Scancell Holdings in an all-stock deal. Neuphoria shares jumped 15%.Agilon Health (AGL) shares fell 14% after Citigroup downgraded the stock to sell from neutral and lifted its price target to $105 from $80.
Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.9%.The iShares Biotechnology ETF (IBB) climbed up 1%.In corporate news, Thermo Fisher Scientific (TMO) shares jumped past 8% after it reported higher fiscal Q2 adjusted earnings and revenue.Quest Diagnostics (DGX) shares rose 6.6% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Neuphoria Therapeutics (NEUP) and Scancell Holdings said Thursday they have struck an all-stock merger deal in which Scancell will acquire Neuphoria. Neuphoria shares surged 20%.Westin Acquisition (WSTN) and First Choice Healthcare Solutions said they have agreed to merge to create a publicly traded healthcare and wellness company. Shares edged up 0.2%.
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $226.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $223.20, Change: $+13.37, Percent Change: +6.37%
Healthcare stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.Thermo Fisher Scientific (TMO) shares were up more than 6% after the company reported higher fiscal Q2 adjusted earnings and revenue.West Pharmaceutical Services (WST) stock was up more than 8% after the company posted higher Q2 adjusted earnings and net sales, and increased its 2026 guidance.Quest Diagnostics (DGX) shares were up more than 7% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $226.07, according to analysts polled by FactSet.Price: $205.91, Change: $-0.09, Percent Change: -0.04%
Quest Diagnostics (DGX) has expanded access to its oncology testing for solid tumor cancers through Flatiron Health's electronic oncology medical record platform OncoEMR MPI, it said Wednesday.The integration is expected to allow 4,700 clinicians within the Flatiron network of 1,600 cancer care locations in the US to quickly access Quest's services without leaving their existing workflow, the company said.Certain providers are now able to order and receive results from Quest using the OncoEMR MPI as part of a pilot program, Quest said, adding that it plans to launch the full OncoEMR MPI integration to providers nationwide in H2.Shares of Quest Diagnostics were down 0.7%.Price: $210.12, Change: $-1.41, Percent Change: -0.66%
Quest Diagnostics (DGX) received approval from the New York State Department of Health for its Haystack MRD circulating tumor DNA test, which is used to detect residual or recurrent disease in patients with solid tumors, the company said Wednesday.The approval expands Haystack MRD availability to New York, making the test accessible in all 50 US states after being offered in 49 states and the District of Columbia since late 2024, the company said.Price: $203.85, Change: $+6.66, Percent Change: +3.38%
J. E. Davis, Director, Chief Executive Officer and President, on June 01, 2026, sold 10,000 shares in Quest Diagnostics (DGX) for $1,941,400. Following the Form 4 filing with the SEC, Davis has control over a total of 132,423 common shares of the company, with 132,423 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1022079/000159983726000005/xslF345X05/wk-form4_1780439916.xml
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $223.56, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $203.15, Change: $-1.99, Percent Change: -0.97%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month price target at $235. This is based on a forward P/E of 21.9x our 2026 EPS estimate, a premium to DGX's three-year forward average of 16.8x due to our view of strengthening sales and earnings growth, backed by higher health care utilization trends and some regulatory relief due to postponement of lab reimbursement cuts until at least 2027. We think lab testing providers remain a relatively well-positioned area within health care given lower policy risks, supportive testing demand, and attractive earnings growth potential. On a compounded annual basis from 2025-2028, we expect near 8% EPS growth, raising our 2026 EPS to $10.73 from $10.60 and 2027 EPS to $11.50 from $11.42. We also anticipate additional smaller M&A opportunities, along with healthy dividend increases (recent 7.5% boost; shares yield 1.7%) as cash flow generation remains supportive over the near term.
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) decreased 1%.In corporate news, Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a randomized study to support approval of its experimental treatment PBFT02, a move that adds time, cost, and uncertainty, Wedbush said Tuesday in a report. Wedbush downgraded Passage Bio's stock to neutral from outperform and cut its price target to $8 from $32. Passage Bio shares dropped 2.9%.Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.7%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 7%.Quest Diagnostics (DGX) shares popped more than 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $203.42, Change: $+7.11, Percent Change: +3.62%
Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.9%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 8%.Quest Diagnostics (DGX) shares popped 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $204.33, Change: $+8.02, Percent Change: +4.09%
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $205.41, Change: $+9.10, Percent Change: +4.64%
Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.8%.UnitedHealth Group (UNH) stock was up more than 8% after the company reported higher Q1 adjusted earnings and revenue, and increased its 2026 adjusted EPS guidance.Quest Diagnostics (DGX) stock was up more than 3% after the company reported higher Q1 adjusted earnings and net revenue, and raised its 2026 outlook.Danaher (DHR) shares were up 0.8% after the company posted higher Q1 adjusted earnings and sales, and lifted its 2026 adjusted diluted EPS outlook.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Quest Diagnostics (DGX) delivered strong Q1 results with revenue of $2.895B, up 9.2% Y/Y, as robust requisition volume grew 10.9% (+10.8% organic) across its physician, hospital, and consumer segments. Diagnostic Information Services sales rose 9.4% while the adjusted operating margin improved modestly to 15.4% from 15.3% in the prior year. The company demonstrated progress in Advanced Diagnostics with strong demand for AD-Detect Alzheimer's blood tests and launched its AI Companion tool with 350,000 patient engagements since rollout. Management raised 2026 guidance, with the sales growth midpoint rising 0.7% to $11.84B and the adjusted EPS midpoint increasing 1.2% to $10.73, reflecting 7.3% and 8.9% growth, respectively, versus 2025. We await further details on DGX's progress in dialysis lab and water-purity testing services, as well as updates on its questhealth.com consumer channel development in the upcoming earnings call. Shares traded up approximately 3% in premarket action following the strong results.
Quest Diagnostics (DGX) said Thursday that City of Hope is evaluating the Haystack MRD circulating tumor DNA test in a research program to help improve disease management for patients with solid tumor cancers.The company said 14 City of Hope sites across the US are participating in the study, which is expected to enroll around 500 patients with breast, colorectal, ovarian, and prostate cancers.The program will evaluate Haystack MRD in detecting minimal residual disease, monitoring treatment response, and identifying recurrence ahead of standard imaging under neoadjuvant, adjuvant, and post-treatment settings, Quest Diagnostics said.Shares of Quest Diagnostics were up 1% in Thursday trading.Price: $193.42, Change: $+2.00, Percent Change: +1.04%
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $218.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $192.51, Change: $-0.36, Percent Change: -0.19%
